Moleac Announces US FDA Approval of IND Application for Phase 1 Study of MLC1501 Programme in Post-Stroke Recovery SINGAPORE, March 5, 2018 /PRNewswire/ — Moleac, a biopharmaceutical company focused on research and development of new medicines for central nervous...
NeuroAiD at ASEAN Neurological Association Moleac will attend the 12th Biennial Convention of ASEAN Neurological Association (ASNA) & 39th Annual Convention of Philippine Neurological Association (PNA), in Manila, Philippines from 21 to 24 November. Prof. N...
NeuroAiD at Asia Pacific Stroke Conference Renowned clinicians and researchers will present abstracts from the latest studies conducted on NeuroAiD, including the principal investigators of NeuroAiD’s landmark study, CHIMES-E, demonstrating the long-term benefits of a...
NeuroAiD at World Congress of Neurology Moleac’s flagship product, NeuroAiD, will be presented at the 23rd Word Congress of Neurology during oral abstract presentations by A/Prof. Alice Theadom from New-Zealand. A Randomized, Placebo-controlled Pilot Trial to...
NeuroAiD presentations at European Stroke Conference NeuroAiD, Moleac’s main product, will be presented at the 26th European Stroke Conference on 24th May during abstract presentations on the 24th and 26th May by A/Prof. Narayanaswamy Venketasubrmanian: Comparison of...